Monday, February 15, 2021 8:23:43 AM
The FDA pivoted away from their original argument claiming the SVF process creates a drug. They are now claiming SVF manipulates the tissue so that it is no longer the same tissue being replanted back into the same patient. The FDA states the tissue is no longer homologous (having the same relation, position, or structure). The FDA's argument is full of holes as it would also have to include any and all tissue transplantation procedures currently not under guidance of the FDA. The FDA has control over things like implants or surgical equipment, but they do not decide what is acceptable medical practice nor do they determine or tissue classifications.
I have a medial background and can elaborate, but I would suggest you do some DD on your own.
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM